3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myeloproliferative Disorders
2
Leukemia, Myeloid
2
Leukemia
2
Philadelphia Chromosome
1
Leukemia, Myeloid, Chronic-Phase
1
HER2+ Metastatic Breast Cancer
1
Bronchiolitis Obliterans Syndrome
1
Blast Crisis
1
Interventions
fludarabine phosphate
2
Whole-Body Irradiation
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
asciminib
1
Tyrosine Kinase Inhibitors
1
Tacrolimus
1
Specimen Handling
1
Sirolimus
1
Rituximab
1
Pharmaceutical Preparations
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Methotrexate
1
Etoposide
1
Cyclosporine
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
CT-P10
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Chronic-Phase
×
asciminib
×
30 days
×
Clear all
NCT05143840
2026-06-02
ALERTCML
University of Alabama at Birmingham
Phase 2
Recruiting
100 enrolled